ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Paul Haluska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.